USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| May 11, 2022 (est) | Mar 31, 2022 | - | - | $-0.62 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| May 11, 2022 (est) | Mar 31, 2022 | - | $-604.68K | $286.00K |
Foghorn Therapeutics's next estimated earnings date (based on same quarter last year's date) is May 11, 2022 for the fiscal quarter ending Mar 31, 2022.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 4 | $-2.45 | $-3.26 | $-2.09 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2022 | 1 / 0 | $-2.46 | $-2.46 | $-2.43 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 4 | $2.00M | $0.00 | $6.00M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 10, 2022 | Dec 2021 | $-0.49 | - | - |
| Nov 9, 2021 | Sep 2021 | $-0.60 | $-0.71 | -19.33% |
| Aug 10, 2021 | Jun 2021 | $-0.60 | $-0.63 | -5.88% |
| May 11, 2021 | Mar 2021 | $-0.55 | $-0.62 | -12.73% |
| Mar 18, 2021 | Dec 2020 | $-0.45 | $-1.86 | -313.33% |
| Dec 4, 2020 | Sep 2020 | $-2.69 | $-3.12 | -15.99% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 10, 2022 | Dec 2021 | $-2.47 | $-1.96 | - |
| Mar 18, 2021 | Dec 2020 | $-4.41 | $-4.98 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 10, 2022 | Dec 2021 | $170.00K | $-604.68K | - |
| Nov 9, 2021 | Sep 2021 | $170.00K | $41.00K | 0.24% |
| Aug 10, 2021 | Jun 2021 | $279.00K | $279.00K | 1.00% |
| May 11, 2021 | Mar 2021 | $286.00K | $286.00K | 1.00% |
| Mar 18, 2021 | Dec 2020 | $0.00 | $251.00 | - |
| Dec 4, 2020 | Sep 2020 | $0.00 | $179.00 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 10, 2022 | Dec 2021 | $1.19M | $1.32K | -99.89% |
| Mar 18, 2021 | Dec 2020 | $0.00 | $430.00 | - |
FHTX's next estimated earnings date (based on same quarter last year's report date) is May 11, 2022 for the fiscal quarter ending Mar 31, 2022.
Foghorn Therapeutics's previous earnings date was Mar 10, 2022 for its fiscal quarter ended Dec 31, 2021.
Revenues were $-604.68K.
The company reported a net income of $72.08M.FHTX ended the quarter with $58.33M in total debt, a decrease of -27.02% compared to the previous quarter, and an increase of 196.79% compared to the same quarter a year before.
Foghorn Therapeutics's previous annual earnings date was Mar 10, 2022 for its fiscal year ended Dec 31, 2021.
FHTX's earnings per share (EPS) was $-1.96, beating the consensus analysts forecast of $-2.47 by -20.65% , and higher than the previous year's EPS (Dec 2020) by -60.64%.
Revenues were $1.32K, worse than the forecast of $1.19M by -99.89%, and up by 206.74% from previous year's revenue.
The company reported a net income of $-101.32K.
The company ended the fiscal year with $58.33M in total debt, an increase of 196.79% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
